Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 7357495, 9 pages
https://doi.org/10.1155/2017/7357495
Research Article

Heparanase Inhibition Reduces Glucose Levels, Blood Pressure, and Oxidative Stress in Apolipoprotein E Knockout Mice

1Internal Medicine E Department, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
2Internal Medicine A Department, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel
3Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion, Haifa, Israel
4Pathology Department, Rambam Health Care Campus and Rappaport Faculty of Medicine, Technion, Haifa, Israel

Correspondence should be addressed to Shadi Hamoud; li.vog.htlaeh.mabmar@duomah_s

Received 30 April 2017; Revised 7 August 2017; Accepted 17 September 2017; Published 26 October 2017

Academic Editor: Sivagnanam Thamilselvan

Copyright © 2017 Shadi Hamoud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Halliwell, “Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?” The Lancet, vol. 344, no. 8924, pp. 721–724, 1994. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Kaplan and M. Aviram, “Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase,” Clinical Chemistry and Laboratory Medicine, vol. 37, no. 8, pp. 777–787, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. L. O. Dragsted, “Antioxidant actions of polyphenols in humans,” International Journal for Vitamin and Nutrition Research, vol. 73, no. 2, pp. 112–119, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Aviram, M. Kaplan, M. Rosenblat, and B. Fuhrman, “Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development,” Handbook of Experimental Pharmacology, vol. 170, pp. 263–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. S. V. Nigdikar, N. R. Williams, B. A. Griffin, and A. N. Howard, “Consumption of red wine polyphenols reduces the susceptibility of low- density lipoproteins to oxidation in vivo,” American Journal of Clinical Nutrition, vol. 68, no. 2, pp. 258–265, 1998. View at Google Scholar · View at Scopus
  6. M. Aviram and B. Fuhrman, “Wine flavonoids protect against LDL oxidation and atherosclerosis,” Annals of the New York Academy of Sciences, vol. 957, no. 1, pp. 146–161, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Aviram, L. Dornfeld, M. Rosenblat et al., “Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice,” American Journal of Clinical Nutrition, vol. 71, no. 5, pp. 1062–1076, 2000. View at Google Scholar · View at Scopus
  8. M. Kaplan, T. Hayek, A. Raz et al., “Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis,” Journal of Nutrition, vol. 131, no. 8, pp. 2082–2089, 2001. View at Google Scholar · View at Scopus
  9. M. Aviram, M. Rosenblat, D. Gaitini et al., “Erratum in: Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation,” Clinical Nutrition, vol. 23, no. 3, pp. 423–433, 2008. View at Google Scholar
  10. S. Hamoud, T. Hayek, N. Volkova et al., “Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: A double-blinded, placebo-controlled, randomized, prospective pilot study,” Atherosclerosis, vol. 232, no. 1, pp. 204–210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Vaya, P. A. Belinky, and M. Aviram, “Antioxidant constituents from licorice roots: Isolation, structure elucidation and antioxidative capacity toward LDL oxidation,” Free Radical Biology & Medicine, vol. 23, no. 2, pp. 302–313, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. P. A. Belinky, M. Aviram, B. Fuhrman, M. Rosenblat, and J. Vaya, “The antioxidative effects of the isoflavan glabridin on endogenous constituents of LDL during its oxidation,” Atherosclerosis, vol. 137, no. 1, pp. 49–61, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Hamoud, M. Kaplan, E. Meilin et al., “Niacin administration significantly reduces oxidative stress in patients with hypercholesterolemia and low levels of high-density lipoprotein cholesterol,” The American Journal of the Medical Sciences, vol. 345, no. 3, pp. 195–199, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Bernfield, M. Götte, P. W. Park et al., “Functions of cell surface heparan sulfate proteoglycans,” Annual Review of Biochemistry, vol. 68, pp. 729–777, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ilan, M. Elkin, and I. Vlodavsky, “Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis,” The International Journal of Biochemistry & Cell Biology, vol. 38, no. 12, pp. 2018–2039, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Sasisekharan, Z. Shriver, G. Venkataraman, and U. Narayanasami, “Roles of heparan-sulphate glycosaminoglycans in cancer,” Nature Reviews Cancer, vol. 2, no. 7, pp. 521–528, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Vlodavsky and Y. Friedmann, “Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis,” The Journal of Clinical Investigation, vol. 108, no. 3, pp. 341–347, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. C. R. Parish, C. Freeman, and M. D. Hulett, “Heparanase: A key enzyme involved in cell invasion,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1471, no. 3, pp. M99–M108, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. U. Barash, V. Cohen-Kaplan, I. Dowek, R. D. Sanderson, N. Ilan, and I. Vlodavsky, “Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis,” FEBS Journal, vol. 277, no. 19, pp. 3890–3903, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Sandwall, P. O'Callaghan, X. Zhang, U. Lindahl, L. Lannfelt, and J. Li, “Heparan sulfate mediates amyloid-beta internalization and cytotoxicity,” Glycobiology, vol. 20, no. 5, pp. 533–541, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Zetser, Y. Bashenko, E. Edovitsky, F. Levy-Adam, I. Vlodavsky, and N. Ilan, “Heparanase induces vascular endothelial growth factor expression: Correlation with p38 phosphorylation levels and Src activation,” Cancer Research, vol. 66, no. 3, pp. 1455–1463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Vlodavsky, P. Beckhove, I. Lerner et al., “Significance of heparanase in cancer and inflammation,” Cancer Microenvironment, vol. 5, no. 2, pp. 115–132, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Vlodavsky, M. Blich, J.-P. Li, R. D. Sanderson, and N. Ilan, “Involvement of heparanase in atherosclerosis and other vessel wall pathologies,” Matrix Biology, vol. 32, no. 5, pp. 241–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. I. Lygizos, Y. Yang, C. J. Altmann et al., “Heparanase mediates renal dysfunction during early sepsis in mice,” Physiological Reports, vol. 1, no. 6, 2013. View at Publisher · View at Google Scholar
  25. R. Goldberg, A. M. Rubinstein, N. Gil et al., “Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy,” Diabetes, vol. 63, no. 12, pp. 4302–4313, 2014. View at Publisher · View at Google Scholar
  26. P. Sidaway, “Diabetic nephropathy: Heparanase mediates renal injury,” Nature Reviews Nephrology, vol. 10, no. 9, article 483, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. H. Tao, Z. Wang, and Y. R. Zhou, “Expression of heparanase in kidney of rats with respiratory syncytial virus nephropathy and its relationship with proteinurina,” Sichuan Da Xue Xue Bao Yi Xue Ban, vol. 45, no. 2, pp. 212–215, 2014. View at Google Scholar
  28. S. Assady, J. Alter, E. Axelman et al., “Nephroprotective effect of heparanase in experimental nephrotic syndrome,” PLoS ONE, vol. 10, no. 3, article e0119610, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Szymczak, J. Kuźniar, and M. Klinger, “The role of heparanase in diseases of the glomeruli,” Archivum Immunologiae et Therapia Experimentalis, vol. 58, no. 1, pp. 45–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Van Den Hoven, A. L. Rops, I. Vlodavsky, V. Levidiotis, J. H. Berden, and J. Van Der Vlag, “Heparanase in glomerular diseases,” Kidney International, vol. 72, no. 5, pp. 543–548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Levidiotis, C. Freeman, C. Tikellis, M. E. Cooper, and D. A. Power, “Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis,” Journal of the American Society of Nephrology, vol. 15, no. 1, pp. 68–78, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Levidiotis, J. Kanellis, F. L. Ierino, and D. A. Power, “Increased expression of heparanase in puromycin aminonucleoside nephrosis,” Kidney International, vol. 60, no. 4, pp. 1287–1296, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Masola, G. Zaza, G. Gambaro et al., “Heparanase: a potential new factor involved in the renal epithelial mesenchymal transition (EMT) induced by ischemia/reperfusion (I/R) injury,” PLoS ONE, vol. 11, no. 7, article e0160074, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Kramer, M. Van Den Hoven, A. Rops et al., “Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system,” Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2513–2520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Van Den Hoven, F. Waanders, A. L. Rops et al., “Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species,” Nephrology Dialysis Transplantation , vol. 24, no. 9, pp. 2637–2645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Levidiotis, C. Freeman, C. Tikellis, M. E. Cooper, and D. A. Power, “Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease,” Nephrology, vol. 10, no. 2, pp. 167–173, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. M. J. Van Den Hoven, A. L. Rops, M. A. Bakker et al., “Increased expression of heparanase in overt diabetic nephropathy,” Kidney International, vol. 70, no. 12, pp. 2100–2108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. A. L. W. M. M. Rops, M. J. Van Den Hoven, B. A. Veldman et al., “Urinary heparanase activity in patients with Type 1 and Type 2 diabetes,” Nephrology Dialysis Transplantation , vol. 27, no. 7, pp. 2853–2861, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Shafat, A. Agbaria, M. Boaz et al., “Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function,” PLoS ONE, vol. 7, no. 9, article e44076, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Shafat, N. Ilan, S. Zoabi, I. Vlodavsky, and F. Nakhoul, “Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels,” PLoS ONE, vol. 6, no. 2, article e17312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J. W. A. M. Celie, K. K. Katta, S. Adepu et al., “Tubular epithelial syndecan-1 maintains renal function in murine ischemia/reperfusion and human transplantation,” Kidney International, vol. 81, no. 7, pp. 651–661, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. A. B. Baker, Y. S. Chatzizisis, R. Beigel et al., “Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine,” Atherosclerosis, vol. 213, no. 2, pp. 436–442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Österholm, L. Folkersen, M. Lengquist et al., “Increased expression of heparanase in symptomatic carotid atherosclerosis,” Atherosclerosis, vol. 226, no. 1, pp. 67–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Gil, R. Goldberg, T. Neuman et al., “Heparanase is essential for the development of diabetic nephropathy in mice,” Diabetes, vol. 61, no. 1, pp. 208–216, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Blich, A. Golan, G. Arvatz et al., “Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. e56–e65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. P. Li, E. A. Burdmann, and R. L. Mehta, “Acute kidney injury: global health alert world kidney day steering committee,” Journal of Nephropathology, vol. 2, no. 2, pp. 90–97, 2013. View at Google Scholar
  47. G. P. Kaushal and S. V. Shah, “Challenges and advances in the treatment of AKI,” Journal of the American Society of Nephrology, vol. 25, no. 5, pp. 877–883, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. K. S. Meir and E. Leitersdorf, “Atherosclerosis in the apolipoprotein E-deficient mouse: a decade of progress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 6, pp. 1006–1014, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Dredge, E. Hammond, P. Handley et al., “PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models,” British Journal of Cancer, vol. 104, no. 4, pp. 635–642, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. V. Ferro, L. Liu, K. D. Johnstone et al., “Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis,” Journal of Medicinal Chemistry, vol. 55, no. 8, pp. 3804–3813, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. S. De Frutos, L. Duling, D. Alò et al., “NFATc3 is required for intermittent hypoxia-induced hypertension,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 294, no. 5, pp. H2382–H2390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Aviram and J. Vaya, “Markers for low-density lipoprotein oxidation,” Methods in Enzymology, vol. 335, pp. 244–256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. J. A. Buege and S. D. Aust, “Microsomal lipid peroxidation,” Methods in Enzymology, vol. 52, pp. 302–310, 1978. View at Publisher · View at Google Scholar · View at Scopus
  54. T. N. Wight and M. J. Merrilees, “Proteoglycans in atherosclerosis and restenosis: Key roles for versican,” Circulation Research, vol. 94, no. 9, pp. 1158–1167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. R. K. Vikramadithyan, Y. Kako, G. Chen et al., “Atherosclerosis in perlecan heterozygous mice,” Journal of Lipid Research, vol. 45, no. 10, pp. 1806–1812, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Karlsson-Lindahl, L. Schmidt, D. Haage et al., “Heparanase affects food intake and regulates energy balance in mice,” PLoS ONE, vol. 7, no. 3, article e34313, pp. 1–7, 2012. View at Publisher · View at Google Scholar · View at Scopus